LENZ Therapeutics: MACD Death Cross and KDJ Death Cross Triggered on 15min Chart

LENZ Therapeutics' 15-minute chart has triggered a MACD Death Cross and a KDJ Death Cross at 08/28/2025 14:30, indicating a potential continuation of the downward trend in stock price. The momentum of the stock price is shifting towards the downside and may further decrease.

LENZ Therapeutics (LENZ) has faced a significant technical setback as its 15-minute chart triggered a MACD Death Cross and a KDJ Death Cross at 08/28/2025 14:30, indicating a potential continuation of the downward trend in stock price. This development suggests a shift in momentum towards the downside, potentially leading to further declines in stock value.

Despite the negative technical signals, LENZ Therapeutics has recently received FDA approval for its aceclidine-based eye drop, LNZ100, which is designed to address presbyopia, the inevitable loss of near vision. The approval marks a significant milestone for the company, which has been actively preparing its sales force and executing international commercialization agreements.

The FDA approval of LNZ100 has not only lowered the risk of the investment but has also opened up new opportunities for the company. LENZ Therapeutics has secured partnerships with Lotus Pharmaceuticals for commercialization in Korea and parts of Southeast Asia, and with Laboratoires Théa for commercialization in Canada. Additionally, the company has submitted a New Drug Application (NDA) for LNZ100 in China through its partnership with CORXEL Pharmaceuticals.

LENZ Therapeutics estimates a market size of $3B in the US alone, with a potential to capture 30% of this market. The company is targeting 15,000 eye care professionals (ECPs) and has a sales team of over 100 members, with direct-to-consumer (DTC) strategies planned for Q1 2026. The company's well-funded position, with over $200M in cash as of Q2 2025, provides a solid foundation for its growth plans.

However, the company's technical indicators suggest a challenging period ahead. The MACD Death Cross and KDJ Death Cross are traditionally considered bearish signals, indicating a potential reversal in the stock's trend. Investors should closely monitor these indicators and consider the broader market conditions when making investment decisions.

References:
[1] https://www.marketscreener.com/news/lenz-therapeutics-corporate-presentation-ce7c50dfd98cf621
[2] https://seekingalpha.com/article/4817577-lenz-therapeutics-adjusting-my-position-after-almost-doubling-in-four-months